Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.

PURPOSE We conducted a phase I/II study to evaluate the efficacy of transrectal high intensity focused ultrasound in the treatment of localized prostate cancer and to assess associated complications. The efficacy of a new high intensity ultrasound device was evaluated using post-treatment prostate specific antigen (PSA) levels and histological results from prostate biopsies as end points. MATERIALS AND METHODS A total of 113 transrectal high intensity focused ultrasound sessions were performed in 50 patients with localized prostate cancer, who were not suitable candidates for radical prostatectomy. Of these patients 2 underwent salvage ultrasound treatment for locally recurrent cancer following definitive radiation therapy. Mean plus or minus standard deviation patient age, PSA and prostate volume were 70.7+/-4.54 years, 9.61+/-7.42 ng./ml. and 37.3+/-19.1 cc. The 2 different high intensity ultrasound prototypes were successfully used, and the latter prototype included several safety devices to reduce morbidity. Median followup was 24 months (range 3 to 46). Control parameters were changes in PSA and random control sextant biopsies at 1 to 3, 3 to 12, 12 to 24, 24 to 36 and 36 to 48 months. RESULTS For the evaluation of therapy patients were divided into 4 groups. Group 1 (complete response) included 28 patients (56%) with no residual cancer and PSA less than 4 ng./ml. (mean 0.93), group 2 (biochemical failure) 3 patients (6%) with no residual cancer and PSA greater than 4 ng./ml. (mean 6.22), group 3 (biochemical control) 9 patients (18%) with residual cancer (mean positive biopsy 1.1 of 6) and PSA less than 4 ng./ml. (mean 0.90), and group 4 (failures) 10 patients (20%) with residual cancer (mean positive biopsies 1.9 of 6) and PSA greater than 4 ng./ml. (mean 8.9). Of the 10 cases in group 4 hormone therapy was required in 3 and radiotherapy in 5. Complication rate with the first prototype device was 50% and it decreased to 17% with the second prototype. CONCLUSIONS Morbidity associated with high intensity focused ultrasound treatment is currently minimal. Local control of the localized prostate cancer was observed in groups 1, 2 and 3 (80%). Repeat sessions were deferred in groups 2 and 3 based on changes in PSA. These preliminary data suggest that high intensity focused ultrasound represents a valid alternative treatment strategy for patients with localized prostate cancer who are unsuitable for surgery.

[1]  W J FRY,et al.  Ultrasonic lesions in the mammalian central nervous system. , 1955, Science.

[2]  S. Loric,et al.  Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy , 1995, The Lancet.

[3]  E. Messing,et al.  Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. , 1994, Urology.

[4]  E D Crawford,et al.  Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. , 1995, Urology.

[5]  F. Fry,et al.  High-intensity focused ultrasound in the treatment of experimental liver cancer. , 1991, Archives of surgery.

[6]  A. V. von Eschenbach,et al.  Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy , 1993, Cancer.

[7]  J. Chapelon,et al.  Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. , 1993, Journal of endourology.

[8]  H. Carter,et al.  Natural history of changes in prostate specific antigen in early stage prostate cancer. , 1994, The Journal of urology.

[9]  C. Dinney,et al.  The efficacy and complications of salvage cryotherapy of the prostate. , 1997, The Journal of urology.

[10]  J. Chapelon,et al.  Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. , 1992, European urology.

[11]  M. Marberger,et al.  Effect of high-intensity focused ultrasound on human prostate cancer in vivo. , 1995, Cancer research.

[12]  J. Hugosson,et al.  Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer. , 1996, The Urologic clinics of North America.

[13]  J. Schalken,et al.  Influence of high-intensity focused ultrasound on the development of metastases. , 1997, European urology.

[14]  R. Écochard,et al.  In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. , 1992, Cancer research.

[15]  R. Riffenburgh,et al.  Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. , 1997, The Journal of urology.

[16]  T. Stamey,et al.  The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. , 1993, The Journal of urology.

[17]  A. Hanlon,et al.  Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. , 1996, The Journal of urology.

[18]  R Souchon,et al.  High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. , 1993, European urology.

[19]  W. Fry,et al.  Ultrasonic Lesions in Mammalian Central Nervous System , 1955, Science.

[20]  Rémi Souchon,et al.  The feasibility of tissue ablation using high intensity electronically focused ultrasound , 1993 .

[21]  J M Dubernard,et al.  Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. , 1996, European urology.